Related Experiment Video
Updated: May 21, 2026
05:17
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Spirocyclohexane-Chroman-4-one Derivatives as Selectively Cytotoxic Agents in Breast Cancer Models
Daria A Ipatova1, Viktoria A Ikonnikova2, Kirill D Kungurtsev2
1Department of Chemistry, Moscow State University (MSU), Leninskie Gory, Building 1/3, Moscow 119991, Russia.
ACS Medicinal Chemistry Letters
|May 20, 2026
Summary
Researchers developed novel spirocyclic-chroman-4-one derivatives for targeted cancer therapy. Compound 42 demonstrated selective cytotoxicity against breast cancer cells, reducing toxicity to non-cancerous cells and offering a promising new chemotherapy strategy.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Pharmacology
Background:
- Developing selective anticancer agents is crucial for effective chemotherapy.
- Chroman-4-one scaffolds combined with spirocyclic structures offer potential for enhanced specificity.
- Modulating molecular structure is key to improving drug efficacy and reducing side effects.
Purpose of the Study:
- To design and synthesize novel spirocyclic-chroman-4-one derivatives with selective anticancer activity.
- To optimize lead compounds for reduced toxicity against non-cancerous cells.
- To evaluate the structure-activity relationships of these novel compounds.
Main Methods:
- Synthesis of 28 spirocyclohexane-chroman-4-one derivatives.
- Screening using fluorescence cell coculture assays to identify selective compounds.
- Iterative structure-activity relationship analysis and rational synthesis for optimization.
Main Results:
- Compound 1 showed initial selectivity in a breast cancer model.
- Structural modifications, including carbonyl reduction and dioxolane incorporation, decreased toxicity to VA13 and MCF10A cells.
- Lead compound 42 exhibited potent cytotoxicity against MCF7 cells (IC50 ≈ 3.8 μM) with significantly reduced non-cancerous cell toxicity.
Conclusions:
- Spirocyclic-fused chroman-4-ones represent a promising class of selective cytotoxic agents.
- Rigidifying the molecular scaffold and precise functional group positioning are key strategies for developing targeted cancer therapies.
- The lead compound 42 demonstrates the potential for a new generation of chemotherapy drugs with improved selectivity.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...